Inclusion Criteria:  Male or female patients with a clinical diagnosis of AD for at least 1 year; vIGA score of ≥3 at Screening and Baseline; ≥10% BSA of AD involvement at Screening and Baseline; EASI score ≥16 at Screening and Baseline; History of inadequate response to treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI); Twice daily application of a consistent amount of topical emollient for at least 7 days prior to randomization.  Exclusion Criteria:  Immunosuppressive/immunomodulating drugs, systemic therapies or phototherapy within 4 weeks prior to randomization; Treatment with leukotriene inhibitors within 4 weeks prior to randomization; Treatment with topical therapies (including TCS, TCI, topical phosphodiesterase inhibitors, topical JAK inhibitors) or prescription moisturizers, within 1 week prior to randomization;  Previous treatment at any time prior to randomization with monoclonal antibody / biologic therapeutic agents as follows;  Prior exposure to dupilumab (Dupixent®) which was discontinued due to lack of efficacy, loss of response, or adverse event; Investigational or approved agents targeting interleukins IL-4 or IL-13 ligands or receptors of IL-4 or IL-13, including but not limited to lebrikizumab, tralokinumab or ASLAN004; Other investigational or approved biologic drug within 16 weeks or within 5 half-lives (if known), whichever is longer, prior to the Baseline visit; Cell-depleting biologics, including, but not limited to, rituximab within 6 months prior to the Baseline visit; Inadequate organ function, abnormal lab result, uncontrolled blood pressure or other health condition considered clinically significant by the investigator at the Screening visit; History of HIV, Hepatitis B, Hepatitis C or active/latent Tuberculosis infection; History of immunosuppression including history of invasive opportunistic infections; Treatment with live attenuated vaccine within 8 weeks prior to randomization; Parasitic infection within 4 weeks prior to randomization travel within 3 months prior to randomization to areas of high parasitic exposure; Have skin comorbidities that in the opinion of the Investigator may interfere with study assessments; Pregnant or breastfeeding women; Patients unwilling to use adequate birth control.